The most recent AMA CPT editorial meeting was February 5-6 in Palm Springs, and at day 14, February 20, they've released the Summary of Panel Actions.
Dozens of PLA codes were voted on, but specific results and final text edits won't appear til March 30/April 1.
Here is the home page for Panel Actions:
https://www.ama-assn.org/about/cpt-editorial-panel/summary-panel-actions
And here is the February 2026 edition:
https://www.ama-assn.org/system/files/feb-2026-summary-of-panel-actions.pdf
The calendar had 69 items. By my count there were 27 withdrawals, and 5 postponed (including the exciting, #14 revisions to appendectomy.) Only 4 codes were rejected.
Big News: WSI AI Code Accepted as Category III
People in the digital imaging / whole slide imaging / AI field got some PLA codes several years ago, and then the PLA group appeared to reject further PLA applicants. One code was rejected as a MAAA code in September 2025.
But now, Valar Labs with tab 45 gets two codes for "response to immunotherapy, non muscle invasive bladder cancer" (X568T, X569T. This validates that AMA CPT will accept slide-based AI services as Category III. I believe CMS should be able to put this through the CLFS (clin lab) pricing process if MA gets the code to CMS in time. (Normally, they get May lab codes to CMS by late May, but Category III codes from February and May don't publish til july 1 and aren't effective til the next January 1). (There's precedent, since CMS put quite a few older, PLA-system WSI codes on the CLFS).
Interesting AI PET Code
See also Tab 64; AI Heterogeneity of Treatment Response in Metastatic Cancer. Code X567T was accepted. I was hugely relieved, because this code fell into a protracted debate process at the Palm Spring meeting. I believe this is the AIQ Solutions service, 'TRAQinform IQ" which is an FDA-cleared software that identifies and tracks multiple metastatic lesions across multiple PET scans, determining both growth and shrinkage as well as FDG intensivity. (As I understand it, radiologists do compare new PET scans to priors, but I assume can't spend hours tracking and measuring every lesion, which a computer can.) I can't speak to how impactful TRAQinform is, since I'm neither an oncologist nor a radiologist, but I was very happy it won at least the status of a Cat III code.
